Roth Capital Has Negative Outlook of CELZ FY2028 Earnings

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Analysts at Roth Capital reduced their FY2028 earnings estimates for shares of Creative Medical Technology in a research report issued to clients and investors on Wednesday, February 12th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of $6.02 for the year, down from their prior estimate of $6.34. The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.19) per share. Roth Capital also issued estimates for Creative Medical Technology’s FY2029 earnings at $7.83 EPS.

Creative Medical Technology Price Performance

Shares of NASDAQ CELZ opened at $4.59 on Friday. Creative Medical Technology has a 1 year low of $1.96 and a 1 year high of $10.28. The firm has a fifty day moving average price of $2.62 and a 200-day moving average price of $3.06.

Institutional Investors Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Geode Capital Management LLC bought a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned approximately 0.59% of Creative Medical Technology at the end of the most recent quarter. 1.42% of the stock is owned by institutional investors and hedge funds.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.